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induction of cytotoxic T-lymphocyte 
responses Upon subcutaneous 
administration of a subunit Vaccine 
adjuvanted With an emulsion 
containing the Toll-like receptor 3 
ligand Poly(i:c)
Signe Tandrup Schmidt1,2, Gabriel Kristian Pedersen2, Malene Aaby Neustrup1, Karen 
Smith Korsholm2, Thomas Rades1, Peter Andersen2, Camilla Foged1† and Dennis 
Christensen2*†
1 Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, 
2 Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
There is an unmet medical need for new subunit vaccines that induce cytotoxic 
T-lymphocyte (CTL) responses to prevent infection with a number of pathogens. 
However, stimulation of CTL responses via clinically acceptable subcutaneous (s.c.) and 
intramuscular (i.m.) injection is challenging. Recently, we designed a liposomal adjuvant 
[cationic adjuvant formulation (CAF)09] composed of the cationic lipid dimethyldiocta-
decylammonium (DDA) bromide, a synthetic monomycoloyl glycerol analog and poly-
inosinic:polycytidylic acid, which induce strong CTL responses to peptide and protein 
antigens after intraperitoneal administration. By contrast, CAF09 does not stimulate CTL 
responses upon s.c. or i.m. injection because the vaccine forms a depot that remains at 
the injection site. Hence, we engineered a series of nanoemulsions (CAF24a–c) based on 
the active components of CAF09. The oil phase consisted of biodegradable squalane, 
and the surface charge was varied systematically by replacing DDA with zwitterionic 
distearoylphosphoethanolamine. We hypothesized that the nanoemulsions drain to the 
lymph nodes to a larger extent than CAF09, upon s.c. co-administration with the model 
antigen chicken egg ovalbumin (OVA). This results in an increased dose fraction that 
reaches the draining lymph nodes (dLNs) and subsequently activates cross-presenting 
dendritic cells (DCs), which can prime CTL responses. Indeed, the nanoemulsions 
induced antigen-specific CD8+ T-cell responses, which were significantly higher than 
those stimulated by OVA adjuvanted with CAF09. We explain this by the observed rapid 
localization of CAF24a in the dLNs and the subsequent association with conventional 
DCs, which promotes induction of CTL responses. Uptake of CAF24a was not specific 
for DCs, because CAF24a was also detected with B cells and macrophages. No mea-
surable dose fraction of CAF09 was detected in the dLNs within the study period, and 
CAF09 formed a depot at the site of injection. Importantly, s.c. vaccination with OVA 
adjuvanted with CAF24a induced significant levels of specific lysis of antigen-pulsed 
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inTrODUcTiOn
Vaccine-mediated induction of antigen-specific cytotoxic 
T-lymphocyte (CTL) responses is considered essential for pre-
venting and/or treating a number of intracellular infections and 
cancers (1, 2). Stimulation of CTL responses against exogenously 
derived vaccine antigens remains a challenge, although a number 
of recent studies suggest that this can be achieved by activating 
specific innate immune pathways (3, 4). Specialized CD8α+ and 
CD103+ dendritic cell (DC) subsets are capable of priming CTL 
responses via the so-called cross-priming pathway (1, 2, 5). 
Cross-presenting DCs can present peptides from exogenously 
derived antigens on major histocompatibility complex (MHC)-I, 
which in combination with co-stimulatory signals prime antigen-
specific CD8+ T cells that subsequently differentiate into CTLs 
(2). It is generally recognized that CD8α+ DCs reside in the lymph 
nodes (LNs), whereas CD103+ DCs primarily localize to mucosal 
sites and the skin, from where they migrate to the draining lymph 
nodes (dLNs) upon activation (6). Cross-presentation of vaccine 
antigens by DCs can be enhanced by simultaneous activation 
of toll-like receptor (TLR)3, which is expressed at high levels in 
the endosomes of cross-priming DCs. Double-stranded RNA 
binds and activates TLR3, which triggers intracellular signaling 
cascades and ultimately upregulates the expression of type I inter-
ferons (IFNs) (7, 8). Thus, targeting of vaccines to LN-resident, 
CD8α+ DCs upon subcutaneous (s.c.) and intramuscular (i.m.) 
immunization is a promising strategy for induction of strong, 
systemic CTL responses.
Recently, we designed a liposomal cationic adjuvant formulation 
(CAF)09, composed of dimethyldioctadecylammonium (DDA) 
bromide, the synthetic monomycoloyl glycerol (MMG) analog 
MMG-1, and the synthetic TLR3 agonist polyinosinic:polycytidylic 
acid [poly(I:C)] electrostatically adsorbed to the DDA head-
groups, which induces remarkably strong antigen-specific 
CD8+ T-cell responses upon co-administration with antigen by 
intraperitoneal (i.p.) injection (9). By contrast, CAF09-adjuvanted 
antigen induces only very weak CD8+ T-cell responses upon s.c. 
and i.m. immunization (9). This is likely a consequence of the 
vaccine forming a depot at the site of injection (SOI) (10), caused 
by interaction between the cationic adjuvant and interstitial pro-
teins, eventually leading to aggregation and depot formation (11). 
Depot formation has been shown to prevent free drainage of the 
vaccine from the SOI via the lymphatics to the dLNs, which is a 
prerequisite for targeting cross-priming CD8α+ DCs localized in 
the dLNs and the spleen (5). The depot-forming ability has been 
shown to depend mainly on two physicochemical properties of 
liposomal adjuvants, i.e., the surface charge and the lipid bilayer 
fluidity (11, 12). In addition, the size of particle-based vaccines 
influences the drainage properties, and nanoparticles with diam-
eters between approximately 40 and 200 nm have been shown to 
drain more efficiently from the SOI to the dLNs than larger-sized 
nanoparticles (5, 13), because they can enter the lymphatics via 
gaps in the vascular endothelium of the lymphatic ducts (14).
Hence, we hypothesized that nanoemulsion adjuvants induce 
CD8+ T-cell responses upon s.c. immunization, because oil-in-
water (o/w) emulsions have fast drainage kinetics due to their oily 
nature and relatively small droplet size (less than approximately 
200 nm). For example, the squalene-based emulsion MF59® has 
been shown to be cleared rapidly from the SOI by free drainage 
and/or uptake and transport by neutrophils (15, 16). The dose 
fraction reaching the dLNs by free drainage may thus be enhanced 
by reducing the average size of the oil droplets below 200 nm, e.g., 
by high-pressure homogenization or sonication (17). Examples 
of marketed emulsion-based vaccine adjuvants are the o/w emul-
sions, MF59® and AS03®, which contains biocompatible squalene 
as the oil phase, and they have been reported to induce mainly 
humoral immune responses (17–20).
In a recent study, we designed nanoemulsions composed of 
unsaturated squalene, or the saturated analog squalene, as the oil 
phase, which was emulsified with surfactant mixtures containing 
four different components (i) polysorbates (Tween®) and sorbi-
tans (Span®), (ii) the saturated cationic lipid DDA or its unsatu-
rated analog dioleoyldimethylammonium chloride, (iii) the 
saturated zwitterionic distearoylphosphoethanolamine (DSPE) 
or its unsaturated analog dioleoylphosphoethanolamine, and (iv) 
the immunostimulatory lipid MMG-1. We measured antigen-
specific CD4+ T-cell responses for the positively charged, unsatu-
rated formulations upon s.c. immunization with the Chlamydia 
trachomatis major outer membrane protein-based fusion antigen 
CTH522 (21–23).
The aim of this study was to design and characterize novel 
nanoemulsion formulations (CAF24a–c) based on our recently 
optimized cationic emulsion (21) and the immunostimula-
tory components of CAF09. Furthermore, the adjuvanticity of 
splenocytes were induced after, which was not observed for OVA adjuvanted with 
CAF09. Thus, CAF24a is a promising adjuvant for induction of CTL responses upon s.c. 
and i.m. immunization, and it offers interesting perspectives for the design of vaccines 
against pathogens for which CTL responses are required to prevent infection.
Keywords: subunit vaccine, adjuvant, nanoemulsion, cytotoxic T-lymphocytes, formulation, poly(i:c)
Abbreviations: Ab, antibody; CAF, cationic adjuvant formulation; CFSE, carboxy-
fluorescein succinimidyl ester; cryo-TEM, cryo-transmission electron microscopy; 
CTL, cytotoxic T-lymphocyte; DC, dendritic cell; DDA, dimethyldioctadecylam-
monium; DiO, 3,3′-dioctadecyloxacarbocyanine perchlorate; dLN, draining 
lymph node; DSPE, distearoylphosphoethanolamine; ELISA, enzyme-linked 
immunosorbent assay; HSM, high shear mixing; i.d., intradermal; IFN, interferon; 
i.m., intramuscular; i.p., intraperitoneal; i.v., intravenous; LN, lymph node; 
MHC, major histocompatibility complex; MMG, monomycoloyl glycerol; o/w, 
oil-in-water; PBS, phosphate-buffered saline; PDI, polydispersity index; poly(I:C), 
polyinosinic:polycytidylic acid; s.c., subcutaneous; SOI, site of injection; TDB, 
trehalose-6,6′-dibehenate; TLR, toll-like receptor; w/o, water-in-oil; Z-average, 
intensity-weighted average hydrodynamic diameter.
Table 1 | The composition of the emulsions CAF24a–c with different ratios of 
DDA and DSPE.
emulsion caF24a caF24b caF24c
Squalane 10,000 10,000 10,000
Span® 60 960 960 960
Tween® 60 1,040 1,040 1,040
Monomycoloyl glycerol 100 100 100
Poly(I:C) 50 50 50
DDA 200 100 0
DSPE 0 119 237
The values indicate the dose of each component in microgram administered in a 
volume of 100 µl.
CAF, cationic adjuvant formulation; DDA, dimethyldioctadecylammonium; DSPE, 
distearoylphosphoethanolamine.
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CAF24a–c was compared to that of CAF09 in mice. Poly(I:C) was 
incorporated into the nanoemulsions, and their ability to induce 
CD8+ T-cell responses upon s.c. immunization was investigated. 
We hypothesized that nanoemulsions have potential as CTL-
inducing adjuvants, when combined with immunostimulators 
promoting activation of cross-priming DCs, which in this case is 
a combination of MMG-1 and poly(I:C). We show that CAF24a 
drains to the dLNs a few hours after i.m. immunization and 
induces significantly higher and functional antigen-specific CTL 
responses compared to liposome-based CAF09.
MaTerials anD MeThODs
Materials
Squalane, Tween® 60, Span® 60 and γ-irradiated poly(I:C) were 
obtained from Sigma-Aldrich (St. Louis, MO, USA). DDA and 
MMG-1 (24) were purchased from NCK A/S (Farum, Denmark), 
DSPE was obtained from Avanti Polar Lipids (Alabaster, AL, USA), 
and endotoxin-free ovalbumin (OVA) was acquired from Hyglos 
GmbH (Bernried am Starnberger See, Germany). AlexaFluor 
647-conjugated OVA was from ThermoFisher Scientific Inc. 
(Waltham, MA, USA), and 3,3′-dioctadecyloxacarbocyanine 
perchlorate (DiO) was provided by Life Technologies (Nærum, 
Denmark). All other chemicals were purchased from commercial 
suppliers and used at analytical grade.
Preparation of emulsions
Weighed amounts of MMG-1, DDA, and DSPE, respectively, were 
dissolved in 99% (v/v) EtOH and mixed in glass vials (Table 1). 
The surfactant mixtures were dried under a gentle N2 stream for 
2 h followed by air-drying overnight to remove trace amounts of 
solvent eventually resulting in the formation of a lipid film. Span® 
60 was weighed into the dry surfactant mixture, because it is poorly 
soluble in EtOH. The oil phase was weighed into the vial and 
heated to 60°C for 10 min with intermittent vortex mixing to melt 
the surfactants and the oil phase. Poly(I:C) dissolved in water-for-
injection (10 mg/ml) was added to the oil phase, and the mixture 
was heated to 60°C for 10 min with intermittent vortex mixing 
to form a water-in-oil (w/o)-emulsion. The second water phase, 
consisting of Tween® 60 dissolved in Tris-buffer (10 mM, pH 7.4), 
was added to the w/o emulsion. A pre-emulsion was prepared 
by high shear mixing (HSM) using a Heidolph Silent Crusher 
equipped with a 6F shearing tool (Heidolph Instruments GmbH, 
Schwabach, Germany) at 60°C and 26,000 rpm for 5 min, and it 
was subsequently microfluidized six times at 20,000 psi using a 
LV1 Low Volume Homogenizer (Microfluidics, Westwood, MA, 
USA). Fluorescently labeled CAF24a used for in  vivo tracking 
studies was prepared by addition of DiO dissolved in EtOH dur-
ing the preparation of the lipid film, resulting in a concentration 
of 0.03 mg/ml in the final emulsion.
Preparation of caF09
Weighed amounts of DDA and MMG-1 were dissolved in 99% 
(v/v) EtOH and mixed in a glass vial at an 82:18  M ratio. The 
lipid mixture was dried under a gentle N2 stream for 2 h followed 
by air-drying overnight to remove trace amounts of solvent. The 
lipid film was rehydrated in Tris-buffer (10 mM, pH 7.4) by HSM 
by using a Heidolph Silent Crusher equipped with a 6F shearing 
tool at 60°C and 26,000 rpm for 15 min. Subsequently, poly(I:C) 
was added slowly to the liposomes with concomitant HSM at 
60°C. The final concentrations in the resulting dispersion were 
2.5/0.5/0.5 mg/ml DDA/MMG-1/poly(I:C). Fluorescently labeled 
CAF09 used for in vivo tracking studies was prepared by addition 
of DiO dissolved in EtOH during the preparation of the lipid film, 
resulting in a concentration of 0.03 mg/ml in the final formulation.
Physicochemical characterization
The intensity-weighted average hydrodynamic diameter 
(z-average) and polydispersity index (PDI) of the emulsions and 
the liposome dispersions were determined by dynamic light 
scattering using photon correlation spectroscopy. Undiluted 
emulsion samples or liposome samples diluted 10 times were 
analyzed at 25°C using a Zetasizer Nano ZS (Malvern Instruments 
Ltd., Worcestershire, UK) equipped with a 633 nm laser and 173° 
detection optics. For undiluted samples, the particle sizes were 
independent of the sample concentration. For viscosity and refrac-
tive indexes, the values of water were used (values provided by 
Malvern Instruments). The particle size distribution was reflected 
in the PDI, which ranges from 0 for a monodisperse to 1.0 for an 
entirely heterodisperse dispersion. The zeta-potentials of the for-
mulations were measured for samples diluted 100 times in milliQ-
water. Zetasizer Software v7.11 (Malvern Instruments Ltd.) was 
used for acquisition and analysis of the data. The morphology of 
the emulsions with or without poly(I:C) was investigated by cryo-
transmission electron microscopy (cryo-TEM) using a Tecnai 
G2 20 TWIN transmission electron microscope (FEI, Hillsboro, 
OR, USA) mounted with a 4 × 4 K charged-coupled device Eagle 
camera from FEI, essentially as described elsewhere (25).
immunization of Mice
All animal experiments were conducted in accordance with 
the national Danish guidelines for animal experiments and EU 
directive 2010/63/EU for animal experiments, as approved by 
the Danish Animal Experiments Inspectorate (license number 
2014-15-2934-01065). All procedures were refined to provide 
maximal comfort and minimal stress for the animals. Female, 
6- to 8-week-old C57BL/6 mice were purchased from Harlan 
(Horst, Netherlands) and allowed free access to food and water. 
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The vaccines were prepared by mixing OVA with adjuvant 30 min 
prior to administration. For in vivo tracking studies, mice were 
immunized once i.m. with 10  µg AF647-OVA, AF647-OVA/
DiO-CAF09, and AF647-OVA/DiO-CAF24a, respectively, in 
each quadriceps. Mice dosed i.m. with 50 µl isotonic Tris-buffer 
served as negative controls. For immunogenicity and in  vivo 
target cell lysis studies, mice were immunized three times at 
2-week intervals s.c. at the base of the tail or i.p. as stated, with 
1 or 10  µg OVA, respectively, in a dose volume of 100  µl. The 
dose of CAF24a–c is given in Table 1. For CAF09, the dose was 
250/50/50 μg DDA/MMG-1/poly(I:C). Unadjuvanted OVA was 
used as a negative control.
Preparation of Organs
The biodistribution of fluorescently labeled vaccines was evaluated 
1, 5, 18, 24, 48, and 120 h after immunization, whereas immune 
responses and antigen-specific lysis of target cells were evaluated 
1 week after the final immunization. The spleens, the inguinal LNs 
(to which vaccines administered s.c. and i.m. are draining), the 
mediastinal and tracheobronchial LNs (to which vaccines admin-
istered i.p. are draining), and blood were harvested. The quadri-
ceps muscles were also harvested for the in vivo tracking studies. 
Single cell suspensions were generated from the spleens and LNs 
by passing the organs through a nylon mesh cell-strainer followed 
by washes with phosphate-buffered saline (PBS, pH 7.4) and RPMI 
1640 (Invitrogen, Carlsbad, CA, USA). The muscles were treated 
with enzymes A, D, and P of the Skeletal Muscle Dissociation Kit 
(Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) accord-
ing to the manufacturer’s instructions. Cells from organs were 
resuspended in RPMI 1640 supplemented with 10% (v/v) heat-
inactivated fetal calf serum, 5 × 10−6 M β-mercaptoethanol, 1% 
(v/v) penicillin–streptomycin, 1% (v/v) sodium pyruvate, 1 mM 
l-glutamine, and 10 mM HEPES (cRPMI), as described elsewhere 
(24). Blood was harvested in EDTA-tubes, and lymphocytes 
were isolated by placing the blood on Lympholyte (Cedarlane, 
Burlington, CA, USA) followed by centrifugation at 900  g for 
20 min. The lymphocytes were subsequently washed with PBS and 
resuspended in FACS-buffer [PBS with 1% (v/v) fetal calf serum].
Pentamer Flow cytometry
The frequency of antigen-specific CD8+ T cells in the blood was 
determined by pentamer flow cytometry. Briefly, 106 cells/well 
were stained with H2-Kb-SIINFEKL:PE (ProImmune, Oxford, 
UK), anti-mouse CD19:PerCP-Cy5.5 antibody (Ab, 1D3) and 
CD4:eFluor780 Ab (RM4-5) from eBiosciences (San Diego, 
CA, USA), and CD8:BV421 Ab (53-6.7), CD44:APC Ab (IM-7), 
and CD62L:FITC Ab (MEL-14), all from BD Biosciences (San 
Jose, CA, USA). Data were acquired by using a BD Fortessa flow 
cytometer (BD Biosciences) and analyzed by using the FlowJo vX 
software (Tree Star, Ashland, OR, USA) identifying immune cell 
subsets (Figure S1 in Supplementary Material).
evaluation of cellular association With 
Fluorescently labeled Vaccines
Single cell suspensions of LNs and quadriceps from mice 
immunized i.m. with fluorescently labeled antigen and adju-
vants were surface stained with anti-mouse Ly6G-PE Ab (1A8), 
CD11b:PerCp-Cy5.5 Ab (M1/70), CD11c:BV421 Ab (HL3), 
I-A/I-E:BV605 Ab (M5/114.15.2), and CD19:BV786 Ab (1D3) 
from BD Biosciences, F4/80:PE-Cy7 Ab (BM8, eBiosciences), and 
Ly6C:APC-Cy7 Ab (HK1.4, BioLegend, San Diego, CA, USA). 
The composition of the panel and the analysis of the cell subsets 
performed essentially as described by Calabro et  al. (16). Data 
were acquired and analyzed as described above (Figures S2 and 
S3 in Supplementary Material).
Quantification of iFn-γ
Single cell suspensions of splenocytes were restimulated with 5 µg 
SIINFEKL (GenScript, Piscataway, NJ, USA) in cRPMI in 96-well 
plates containing 2 ×  105 cells/well for 4  days at 37°C. cRPMI 
medium and Concanavalin A (Sigma-Aldrich) were used as 
negative and positive controls, respectively. The IFN-γ concentra-
tion in the supernatant was measured by using an enzyme-linked 
immunosorbent assay (ELISA) kit (BD Biosciences), as previously 
described (24). Briefly, MaxiSorp plates were coated with capture 
anti-mouse IFN-γ Ab overnight at 4°C. Following blocking with 
2% (w/v) skim-milk powder dispersed in PBS, the supernatant 
was added to the wells at eight-time dilution in PBS. After 2 h of 
incubation at room temperature, biotin-conjugated anti-mouse 
IFN-γ detection Ab was added, followed by streptavidin-
conjugated horseradish peroxidase. Detection was performed 
with 3,3′,5,5′-tetramethylbenzidine (Kem-En-Tec, Taastrup, 
Denmark), and the reaction was stopped with 0.2 M H2SO4. The 
optical density was read at 450 nm with 570 nm correction.
lysis of Target cells In Vivo
Lysis of target cells in vivo was measured essentially as described 
elsewhere (26). Briefly, splenocytic single cell suspensions from 
naïve mice were stained with either 0.5 µM carboxyfluorescein 
succinimidyl ester (CFSE, Invitrogen, referred to as CFSElo) or 
5  µM CFSE combined with subsequent pulsing for 1.5  h with 
10 µg/ml SIINFEKL peptide (referred to as CFSEhi). The CFSElo 
and CFSEhi cells were mixed at a 1:1 number ratio. A total 
number of 1.6 × 106 cells in 200 µl were injected intravenously 
(i.v.) into naïve mice and mice immunized with CAF24a- and 
CAF09-adjuvanted OVA (1 μg/dose). Mice were euthanized 24 h 
after injection, and the percentages of CFSElo and CFSEhi cells of 
the total CFSE+ population in the spleen, dLNs, and blood were 
determined by flow cytometry. Specific lysis was calculated as the 
ratio of CFSEhi to CFSElo cells in immunized mice, as compared 
to the average CFSEhi/CFSElo ratio in naïve mice (Figure S4 in 
Supplementary Material).
statistical analysis
One-way ANOVA followed by Tukey’s multiple comparisons 
test was used to analyze the difference between the individual 
groups, and Spearman’s correlate statistics were performed using 
GraphPad Prism version 7.04 for Windows (GraphPad Software, 
La Jolla, CA, USA).
resUlTs
We prepared a series of nanoemulsions based on our previously 
optimized emulsion (21) and the components of CAF09, and 
FigUre 1 | Representative cryo-transmission electron microscopy images of cationic adjuvant formulation 24a with (left) and without (right) poly(I:C). The beam 
damage observed in association with the emulsion droplets (arrows) may be a result of the presence of electron-dense poly(I:C).
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they were characterized with respect to physicochemical proper-
ties and adjuvanticity, which was evaluated in mice upon s.c. 
administration. The nanoemulsions were composed of the oil 
squalane, the surfactants Tween® 60, Span® 60, DDA, DSPE, and 
the immunostimulators MMG-1 and poly(I:C), and they were 
prepared by high pressure microfluidization. We included in our 
previously published emulsification procedure (21); (i) addition 
of poly(I:C) dissolved in a small volume of water-for-injection 
(w1) to the oil phase (o) and (ii) a subsequent heating step with 
intermittent vortexing to maximize attractive electrostatic 
interaction between polyanionic poly(I:C) and cationic DDA. 
This w1/o single emulsion was added to a second outer water 
phase (w2), which results in the formation of a (transient) w1/o/
w2 double emulsion. The morphology of CAF24a was evaluated 
by cryo-TEM (Figure 1, left), which confirmed that the formula-
tion was indeed an o/w emulsion. From the cryo-TEM pictures, 
it is not possible to deduce whether the resulting emulsion is a 
single or a double emulsion. The electron beam caused sample 
damage as a result of the presence of electron-dense poly(I:C) 
(Figure 1, left), which was not observed for a comparable and 
less electron-dense emulsion without poly(I:C) at identical 
experiment conditions (Figure  1, right). This suggests that 
poly(I:C) is co-localized with the oil droplets. Poly(I:C) may 
theoretically be localized in three different regions of the emul-
sion; (i) in the oil phase in a net hydrophobic complex with DDA, 
(ii) at the o/w interface in a net charged complex with DDA, and/
or (iii) in the water phase. However, further studies are required 
to determine the exact spatial localization of poly(I:C) in the 
emulsions as a function of the poly(I:C):DDA molar ratio. This 
could be evaluated by using, e.g., confocal microscopy to deter-
mine the localization of fluorescently labeled poly(I:C) within 
the water phase and the oil phase, as previously described (25). 
Furthermore, the concentration of poly(I:C) in the water phase 
and in the oil phase may be quantified by UV spectroscopy, as 
previously reported (25).
High-pressure microfluidization manufacturing of the emul-
sions resulted in average hydrodynamic droplet diameters below 
approximately 200  nm (Table  2). In comparison, CAF09 pre-
pared by HSM displayed larger particles (Table 2). As expected, 
replacing DDA with DSPE resulted in reduced zeta-potentials 
(CAF24b: −19 ± 1 mV, CAF24c: −35 ± 4 mV), while CAF09 was 
highly cationic (45 ± 5 mV).
OVa adjuvanted With caF24a induces 
antigen-specific cD8+ T cells
The immunogenicity of OVA adjuvanted with CAF24a was 
measured upon i.p. administration and compared to the immu-
nogenicity of OVA adjuvanted with CAF09, because we recently 
showed that i.p. administration of CAF09-adjuvanted OVA results 
in induction of remarkably strong OVA-specific CD8+ T-cell 
responses (9). Antigen-specific CD8+ T-cell responses in the blood 
were evaluated by pentamer staining for the dominant SIINFEKL 
CD8+ T-cell epitope in OVA (Figure 2A). Strong antigen-specific 
CD8+ T-cell responses were measured after i.p. immunization 
with CAF24a (Figure 2B), which were of comparable magnitude 
to the responses stimulated by CAF09-adjuvanted OVA (9). 
Immunization i.p. with unadjuvanted OVA was previously shown 
not to induce OVA-specific CD8+ T-cell responses (10).
The immunogenicity of the CAF24a–c-adjuvanted OVA 
upon s.c. immunization was compared to the immunogenicity of 
CAF09-adjuvanted OVA and unadjuvanted OVA (Figures 2A,B). 
Interestingly, CAF24a and CAF24b induced significantly stronger 
SIINFEKL-specific CD8+ T-cell responses than CAF09 after s.c. 
immunization (Figure 2B). In addition, OVA/CAF24c induced 
higher levels of antigen-specific CD8+ T-cell responses compared 
to OVA/CAF09, but the difference was not statistically significant 
(Figure 2B).
We measured the secretion of IFN-γ from splenocytes res-
timulated with SIINFEKL by ELISA. Data showed that i.p. immu-
nization with OVA/CAF24a resulted in strong antigen-specific 
IFN-γ responses in the spleen (Figure 2C). For the s.c. immu-
nized mice, OVA/CAF24b induced significantly higher IFN-γ 
levels, as compared to the levels for the OVA/CAF09-immunized 
group, while the levels of IFN-γ were not significantly increased 
for OVA adjuvanted with CAF24a or CAF24c (Figure 2C). The 
Ab responses against OVA, measured as total IgG levels, were low 
for all groups (results not shown).
FigUre 2 | (a) Representative pseudocolor dot plots of activated ovalbumin (OVA)-specific CD8+ T cells (squared gate) induced by OVA/cationic adjuvant 
formulation (CAF)24a administered intraperitoneal (i.p.), and unadjuvanted OVA or OVA adjuvanted with CAF09 and CAF24a, respectively, administered 
subcutaneous (s.c.). (b) Frequency of OVA-specific CD8+ T cells in the blood from individual mice as determined by SIINFEKL-pentamer staining. (c) Secretion of 
interferon (IFN)-γ from splenocytes restimulated with SIINFEKL measured by using enzyme-linked immunosorbent assay (ELISA). The vaccines were administered 
s.c. and i.p. where indicated. *p ≤ 0.05, ***p ≤ 0.001, one-way ANOVA compared to OVA/CAF09 s.c., OVA/CAF24 i.p. was not included in the analysis, but is 
included for illustration. n = 8, data were pooled from two independent experiments (triangles and squares). Lines with bars represent mean values ± SEM.
Table 2 | Average hydrodynamic diameter (z-average, d.nm), PDI, and zeta-
potential (zp, mV) of CAF09 and CAF24a–c.
DDa:DsPe molar  
ratio
z-average (d.nm) PDi Zp (mV)
CAF09 – 393 ± 39 0.21 ± 0.02 45 ± 5
CAF24a 2:0 133 ± 67 0.46 ± 0.03 28 ± 11
CAF24b 1:1 93 ± 10 0.32 ± 0.07 −19 ± 1
CAF24c 0:2 96 ± 5 0.31 ± 0.06 −35 ± 4
n = 3, data represent mean values ± SD.
PDI, polydispersity index; CAF, cationic adjuvant formulation; DDA, 
dimethyldioctadecylammonium; DSPE, distearoylphosphoethanolamine.
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caF24a rapidly localizes in the  
dlns Upon i.m. administration
The difference in the immune responses induced with CAF24a 
and CAF09-adjuvanted OVA was investigated further by evaluat-
ing the distribution and cellular association in muscle and ingui-
nal dLNs of fluorescently labeled AF647-OVA adjuvanted with 
DiO-CAF24a and DiO-CAF09, respectively, for 120 h following 
i.m. administration. We chose the i.m. immunization route for 
these studies because it enables us to evaluate influx of innate 
immune cells by excision of the SOI. The vaccine (adjuvant and 
antigen) localized rapidly in the dLNs upon i.m. immunization 
with OVA/CAF24a, whereas OVA/CAF09 remained at the SOI 
(Figure 3A) as previously reported (10). The CAF24a-adjuvanted 
vaccine was detected in the dLNs already 1 h after immunization, 
suggesting that either fast free drainage or transport mediated 
by draining cells account for the relocalization to the dLNs. 
At this time point, OVA/CAF24a was mainly associated with 
B cells and macrophages, whereas there were very few vaccine-
positive inflammatory monocytes and neutrophils (Figure S5 
in Supplementary Material). This contrasts the finding for the 
squalene emulsion-based adjuvant MF59®, that neutrophils and 
monocytes transport MF59® and antigen from the SOI to the 
dLN (16). However, the lack of vaccine-positive neutrophils 
and inflammatory monocytes in the dLNs upon immunization 
with OVA/CAF24a might be a consequence of very rapid cell 
lysis en route or upon entry in the dLNs, which may eventually 
result in the release of unprocessed vaccine particles in the LNs 
(Figure S5 in Supplementary Material). At later time points, the 
rapid localization of OVA/CAF24a in the dLNs was accompa-
nied by a simultaneous fast association of the vaccine with the 
cDCs (CD11b+, CD11c+, MHC-II+, Figure 3B). These include, 
FigUre 3 | (a) Fraction of vaccine+ (adjuvant+, antigen−/+) lymphocytes, and number of (b) vaccine+ cDCs (CD11b+, CD11c+, MHC-II+), (c) vaccine+ B cells 
(CD19+), (D) vaccine+ inflammatory monocytes (CD11b+, Ly6C+), (e) vaccine+ neutrophils (Ly6G+), and (F) vaccine+ macrophages (CD11b+, F4/80+) in the draining 
lymph nodes following intramuscular immunization with ovalbumin (OVA) adjuvanted with cationic adjuvant formulation (CAF)09 and CAF24a, respectively, as 
compared to naïve mice and mice immunized with unadjuvanted OVA. n = 2 (naïve, unadjuvanted OVA) and n = 6 (OVA/CAF24a and OVA/CAF09), data points 
represent mean ± SEM.
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among others, cross-priming CD8α+ and CD103+ DC subsets. 
The CAF24a-adjuvanted vaccine did also associate with a large 
number of B cells (CD19+). It is likely that there is no preferential 
association with specific cell subsets, but that the vaccine rather 
associates with a number of different types of immune cells 
found in the different LN compartments (Figure  3C). While 
cDCs and B cells were not recovered in the muscle in appreciable 
amounts (results not shown), vaccine association with inflam-
matory monocytes, macrophages, and neutrophils was detect-
able in both the muscle and dLNs (Figures 3D–F and 4A–C), 
indicating that transport of cell-associated vaccine from the SOI 
to the dLNs is mediated by one or several of these subsets. By 
contrast, OVA/CAF09 did not localize to the dLNs at detectable 
levels within the 120 h study period (Figure 3), indicating that 
CAF09 remains as a depot at the SOI within the duration of the 
study.
caF24a associates With immune cells in 
Muscle 1 h after administration, Whereas 
caF09 association to immune cells is 
First Detectable after 18 h
At the SOI, we could detect OVA/CAF24a in neutrophils and 
macrophages shortly after immunization, while OVA/CAF09 
FigUre 4 | Number of (a) vaccine+ (adjuvant+antigen+) neutrophils, (b) vaccine+ macrophages, and (c) vaccine+ inflammatory monocytes in muscle following 
intramuscular administration of ovalbumin (OVA) adjuvanted with cationic adjuvant formulation (CAF)09 and CAF24a as compared to naïve mice and mice 
immunized with unadjuvanted OVA. (D) Mean fluorescence intensity (MFI) of OVA in vaccine+ muscle cells. n = 2 (naïve, unadjuvanted OVA) and n = 6 (OVA/CAF24a 
and OVA/CAF09). Data points represent mean ± SEM.
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association to neutrophils, macrophages, or inflammatory mono-
cytes was first measured 18 h after administration (Figures 4A–C; 
Figure S6 in Supplementary Material). Thus, the rapid uptake of 
OVA/CAF24a by neutrophils and macrophages may account for 
the early localization of vaccine in the dLNs, although significant 
numbers of neutrophils could not be measured in the dLNs at this 
time point (Figure 3E). Interestingly, the fraction of OVA associ-
ated with each vaccine+ cell [measured as the mean fluorescence 
intensity (MFI)] was high in the OVA/CAF09-immunized group 
during the entire study period, while cells from mice immunized 
with OVA/CAF24a displayed only low levels of OVA throughout 
the study period (Figure 4D). This indicates that CAF09 forms 
a depot within the muscle cells at the SOI, as shown in previous 
studies with CAF09 and other cationic liposomal formulations 
(10–12). By contrast, a small fraction of OVA was retained at 
the SOI after immunization with OVA/CAF24a, although an 
appreciable number of cells was adjuvant positive (Figure 4). The 
relatively high OVA MFI-values measured in the OVA/CAF09-
immunized mice, as compared to the OVA/CAF24a-immunized 
mice, may also be a result of aggregation of CAF09 upon addition 
of OVA, which has been observed in previous studies (10). The 
absolute values for the MFI of CAF09 and CAF24a cannot be 
directly compared because the specific compositions of the adju-
vants affect the overall fluorescence intensity of the formulations.
immunization s.c With OVa/caF24a 
results in induction of significantly 
stronger cTl responses Than 
immunization With OVa/caF09
The effector function of the OVA-specific CD8+ T cells induced by 
immunization with CAF24a- and CAF09-adjuvanted OVA (OVA 
dose of 1  µg), respectively, was evaluated as the ratio between 
CFSEhi, SIINFEKL-pulsed splenocytes and CFSElow non-pulsed 
splenocytes from naïve mice, which were recovered from immu-
nized mice 24 h after i.v. injection of 1.6 × 106 cells. A significantly 
higher antigen-specific lytic activity was measured for mice 
immunized with CAF24a-adjuvanted OVA, as compared to that 
for mice immunized with CAF09-adjuvanted OVA, in the spleen, 
dLNs, and blood following s.c. immunization (Figures  5A–C). 
The specific lysis following s.c. immunization with both adjuvants 
did not match the corresponding responses following i.p. immu-
nization, which resulted in 100% specific lysis (results not shown).
To evaluate the effector function of the antigen-specific CD8+ 
T  cells (capacity to lyse antigen-presenting target cells), a dose 
of 1 µg OVA was used, which resulted in lower levels of antigen-
specific CD8+ T  cells in the blood (Figure  5D) as compared to 
immunization with a dose of 10 µg OVA used in the immunization 
studies presented above (Figure 4B). However, there was a positive 
FigUre 5 | Specific lysis of SIINFEKL-loaded splenocytes 24 h after intravenous injection in (a) spleen, (b) draining lymph nodes, and (c) blood in naïve mice and 
following subcutaneous immunization with 1 μg/dose OVA, OVA/cationic adjuvant formulation (CAF)09, and OVA/CAF24a, respectively. (D) Comparison of the levels 
of SIINFEKL-specific CD8+ T cells and the specific lysis in the blood in individual mice. Correlation for the combined groups: Spearman, p = 0.0001. The results are 
from one of two repeated studies. n = 6, lines with bars represent mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ****p ≤ 0.0001, one-way ANOVA with Tukey’s post-test.
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correlation (Spearman, p = 0.0001) between the percentage of anti-
gen-specific CD8+ T cells and antigen-specific lysis (Figure 5D).
DiscUssiOn
The present study provides proof-of-concept that nanoemul-
sions containing poly(I:C) induces antigen-specific CD8+ T-cell 
responses upon s.c. immunization, which appeared to have a 
significant antigen-specific lytic effector function in an in  vivo 
assay. Thus, CAF24 might have potential as a CD8+ T-cell induc-
ing adjuvant for i.m. and s.c. administration. The magnitudes of 
the immune responses induced by i.p. immunization with OVA 
adjuvanted with emulsions containing MMG and poly(I:C) 
(CAF24a) were similar to the magnitudes previously measured for 
the liposome-based CAF09 adjuvant (9, 10). This was expected, 
because immunization with a number of different antigens adju-
vanted with CAF09 via the i.p. route has been shown to induce 
very robust and remarkably strong CD8+ T-cell responses (9). The 
magnitude of the CTL responses depends on the administration 
route, with the i.p. route being quantitatively superior to s.c./i.m. 
A likely explanation for this is that the number of targeted cross-
priming DCs in the respective dLNs is highest following i.p. 
immunization due to increased free drainage of vaccine particles.
These results suggest that the adjuvant mechanisms of CAF09 
and CAF24a might be very different, possibly as a result of 
differences in physicochemical properties, eventually being 
decisive for the biodistribution measured upon i.m. administra-
tion. Accumulation of MF59®-adjuvanted, fluorescently labeled 
antigen in dLN-resident macrophages and B  cells has been 
observed 6 h following i.m. immunization (27). A comparable 
biodistribution profile was evident after i.m. immunization 
with a CAF24a-adjuvanted vaccine, which associated with 
lymphocytes and macrophages in the dLNs few hours after 
i.m. administration. By contrast, DDA-based liposomes have 
been shown to form persistent depots at the SOI (12). Upon 
i.m. immunization with CAF24a, a fraction of the vaccine also 
remained at the SOI throughout the entire study period. Thus, the 
formation of a nanoemulsion depot at the SOI does not prevent 
induction of functional CD8+ T-cell responses, possibly because 
it is the drainage kinetics of the vaccine to the dLNs that is rate 
limiting for the induction of CTL responses. The two w/o emul-
sion adjuvants incomplete Freund’s adjuvant and Montanide 
ISA-51, both in combination with a TLR9-ligand, were shown 
to induce significant antigen-specific CD8+ T-cell responses in 
clinical trials (28, 29). The w/o emulsions form persistent depots 
at the SOI (30, 31), indicating that emulsion adjuvants can be 
engineered to have CTL-inducing abilities. However, a drawback 
is that the antigen remaining at the SOI may attract activated 
antigen-specific CD8+ T cells, resulting in systemic depletion of 
antigen-specific CTLs (30). Furthermore, moderate and serious 
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adverse events have been reported in several clinical trials with 
Montanide ISA-51 (32).
Based on the physicochemical properties of the liposomal 
CAF09 and the emulsion-based CAF24a, differences in drain-
ing patterns are expected. CAF09, which is strongly cationic, is 
hypothesized to interact rapidly with negatively charged inter-
stitial proteins upon administration, as previously observed for 
DDA:trehalose-6,6′-dibehenate-liposomes (11). By contrast, the 
emulsion droplets of CAF24a were found to have a reduced zeta-
potential as compared to CAF09, which might be explained by the 
presence of the surfactants Tween® 60 and Span® 60, which shield 
the charge of the cationic headgroups. Furthermore, Tween® 60 
contains three polyethylene glycol moieties, which to some degree 
may prevent aggregation with interstitial proteins. If aggregation 
of the emulsion droplets upon administration is prevented, some 
degree of free drainage to the dLNs may be possible, because the 
particle size is below approximately 200 nm, which is suggested to 
be a prerequisite for entering the lymphatics through the epithe-
lial cell lining of the lymphatic ducts (14, 33). Further studies are 
needed to evaluate the interaction with interstitial proteins and 
the kinetics of antigen/adjuvant processing in order to understand 
the mechanism(s) of antigen association to the adjuvant in vivo.
Both CAF09 and CAF24a associated with neutrophils, mac-
rophages, and inflammatory monocytes at different levels upon 
i.m. administration. Immunization with MF59® also resulted in 
an influx of neutrophils, monocytes, eosinophils, macrophages, 
and mDCs at the SOI (16). In a study evaluating the efficacy 
of a soy bean oil with ginseng root saponin-emulsion as a vac-
cine adjuvant, the significantly increased cytokine levels in the 
muscle SOI 3 h after immunization indicates that macrophages 
are recruited to the SOI (34). Hence, the environment at the SOI 
is dominated by influx of immune cells, which is an expected 
response to the immunostimulatory effects of the adjuvants. Thus, 
the cellular transport and/or free drainage of the emulsion-based 
adjuvant may be rate limiting for the presentation of the vaccine 
to cross-priming DCs. Therefore, transport of intact vaccine 
particles by neutrophils and monocytes might play a role. Thus, 
MF59® is localized in the dLNs in association with neutrophils 
and monocytes a few hours after immunization (16), as shown 
here for CAF24a. Furthermore, intradermally (i.d.) administered 
Mycobacterium bovis bacilli Calmette-Guérin was transported 
to the dLNs by neutrophils entering the SOI (35). The transport 
function by neutrophils might be dependent on the particles or 
pathogens in question, as i.d. administered herpes simplex virus 
type 1 was not transported by neutrophils to the draining lymph 
nodes (dLNs), despite neutrophils entering the SOI (36). These 
results indicate that particles with specific physicochemical prop-
erties are transported to the dLNs by cell-mediated transport, 
which in turn might increase the propensity for targeting and 
activating LN-resident cross-priming DCs.
The antigen-specific lytic response induced by immunization 
with CAF24a correlates with the recovery of the vaccine in the 
dLNs, particularly the fraction of vaccine associated with cDCs. 
This indicates that targeting of LN-resident cross-priming DCs 
increases the chances of inducing a robust CD8+ T-cell response. 
However, targeting of other cells in the LNs might also play a 
role in the induction of CTL responses, e.g., plasmacytoid DCs, 
which are suggested to promote cross-priming facilitated by 
cross-presenting DCs via expression of type I IFNs (37).
cOnclUsiOn
Incorporation of DDA, MMG-1, and poly(I:C) into a squalane-
based nanoemulsion (CAF24a) resulted in a positively charged 
emulsion with an average droplet diameter below 200 nm. Strong 
antigen-specific CTL responses were induced upon s.c. immuniza-
tion with the emulsion, which correlated with the induction of strong 
antigen-specific lytic responses. These responses were significantly 
higher than the responses induced by the liposome-based adjuvant, 
CAF09, which is composed of the same immunostimulatory com-
pounds, indicating that the specific type of delivery system and its 
pharmacokinetics and pharmacodynamics in vivo play important 
roles for induction of CTLs after s.c. administration. Thus, CAF24a 
is a promising candidate adjuvant for vaccines aiming to elicit high 
CTL responses to prevent or treat infectious diseases, because it can 
be administered via the clinically acceptable s.c. and i.m. routes.
eThics sTaTeMenT
All animal experiments were carried out in accordance with 
the national Danish guidelines for animal experiments and EU 
directive 2010/63/EU for animal experiments, as approved by the 
Danish Animal Experiments Inspectorate (license number 2014-
15-2934-01065). All procedures were refined to provide maximal 
comfort and minimal stress for the animals.
aUThOr cOnTribUTiOns
SS, GP, KK, CF, and DC designed the study. SS, GP, and MN 
prepared the laboratory work and analyzed the data. SS, GP, MN, 
CF, and DC interpreted the data. SS, GP, CF, and DC drafted the 
manuscript. SS, GP, KK, TR, PA, CF, and DC provided scientific 
input throughout the study period and draft of the manuscript.
FUnDing
This work was funded by Statens Serum Institut and University 
of Copenhagen (STS). Additional funding was provided by 
Innovation Fund Denmark (grant number 069-2011-1), Centre 
for Nano-vaccine (grant number 09-067052) and ADITEC (EU 
grant number 280873). The funding sources had no involvement 
in the study design; in the collection, analysis, and interpretation 
of the data; in the writing of the report; nor in the decision to 
submit the paper for publication. We wish to thank the staff of the 
adjuvant group at INFIMM, SSI, in particular Janne Rabech and 
Rune Fledelius Jensen. We are also grateful to The Core Facility for 
Integrated Microscopy, Faculty of Health and Medical Sciences, 
University of Copenhagen.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
https://www.frontiersin.org/articles/10.3389/fimmu.2018.00898/
full#supplementary-material.
11
Schmidt et al. Induction of CTL with CAF24a
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 898
reFerences
1. Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting 
functions of dendritic-cell subsets in vivo. Nat Rev Immunol (2007) 7(7):543–
55. doi:10.1038/nri2103 
2. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic 
cells. Nat Rev Immunol (2012) 12(8):557–69. doi:10.1038/nri3254 
3. Jelinek I, Leonard JN, Price GE, Brown KN, Meyer-Manlapat A, Goldsmith PK, 
et al. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce 
dendritic cell cross-presentation, CTL responses, and antiviral protection. 
J Immunol (2011) 186(4):2422–9. doi:10.4049/jimmunol.1002845 
4. Kuchtey J, Chefalo PJ, Gray RC, Ramachandra L, Harding CV. Enhancement 
of dendritic cell antigen cross-presentation by CpG DNA involves type I IFN 
and stabilization of class I MHC mRNA. J Immunol (2005) 175(4):2244–51. 
doi:10.4049/jimmunol.175.4.2244 
5. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, 
kinetics and molecular patterns. Nat Rev Immunol (2010) 10(11):787–96. 
doi:10.1038/nri2868 
6. Edelson BT, Kc W, Juang R, Kohyama M, Benoit LA, Klekotka PA, et  al. 
Peripheral CD103(+) dendritic cells form a unified subset developmen-
tally related to CD8α(+) conventional dendritic cells. J Exp Med (2010) 
207(4):823–36. doi:10.1084/jem.20091627 
7. Davey GM, Wojtasiak M, Proietto AI, Carbone FR, Heath WR, Bedoui S. 
Cutting edge: priming of CD8 T cell immunity to Herpes simplex virus type 
1 requires cognate TLR3 expression in vivo. J Immunol (2010) 184(5):2243–6. 
doi:10.4049/jimmunol.0903013 
8. Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, Alexopoulou L, et al. 
Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 
(2005) 433(7028):887–92. doi:10.1038/nature03326 
9. Korsholm KS, Hansen J, Karlsen K, Filskov J, Mikkelsen M, Lindenstrøm T, 
et  al. Induction of CD8+ T-cell responses against subunit antigens by the 
novel cationic liposomal CAF09 adjuvant. Vaccine (2014) 32(31):3927–35. 
doi:10.1016/j.vaccine.2014.05.050 
10. Schmidt ST, Khadke S, Korsholm KS, Perrie Y, Rades T, Andersen P, et al. The 
administration route is decisive for the ability of the vaccine adjuvant CAF09 
to induce antigen-specific CD8+ T-cell responses: the immunological conse-
quences of the biodistribution profile. J Control Release (2016) 239:107–17. 
doi:10.1016/j.jconrel.2016.08.034 
11. Henriksen-Lacey M, Bramwell VW, Christensen D, Agger EM, Andersen P, 
Perrie Y. Liposomes based on dimethyldioctadecylammonium promote a 
depot effect and enhance immunogenicity of soluble antigen. J Control Release 
(2010) 142(2):180–6. doi:10.1016/j.jconrel.2009.10.022 
12. Christensen D, Henriksen-Lacey M, Kamath AT, Lindenstrøm T, Korsholm KS, 
Christensen JP, et  al. A cationic vaccine adjuvant based on a saturated 
quaternary ammonium lipid have different in vivo distribution kinetics and 
display a distinct CD4 T cell-inducing capacity compared to its unsaturated 
analog. J Control Release (2012) 160(3):468–76. doi:10.1016/j.jconrel.2012. 
03.016 
13. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. 
Nanoparticles target distinct dendritic cell populations according to their size. 
Eur J Immunol (2008) 38(5):1404–13. doi:10.1002/eji.200737984 
14. Swartz MA. The physiology of the lymphatic system. Adv Drug Deliv Rev 
(2001) 50(1–2):3–20. doi:10.1016/S0169-409X(01)00150-8 
15. Tegenge MA, Von Tungeln LS, Mitkus RJ, Anderson SA, Vanlandingham MM, 
Forshee RA, et al. Pharmacokinetics and biodistribution of squalene-contain-
ing emulsion adjuvant following intramuscular injection of H5N1 influenza 
vaccine in mice. Regul Toxicol Pharmacol (2016) 81:113–9. doi:10.1016/j.
yrtph.2016.08.003 
16. Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O’Hagan DT, 
et  al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neu-
trophils and monocytes that participate in antigen transport to draining 
lymph nodes. Vaccine (2011) 29(9):1812–23. doi:10.1016/j.vaccine.2010. 
12.090 
17. Fox C. Squalene emulsions for parenteral vaccine and drug delivery. Molecules 
(2009) 14(9):3286. doi:10.3390/molecules14093286 
18. Brito LA, Malyala P, O’Hagan DT. Vaccine adjuvant formulations: a phar-
maceutical perspective. Semin Immunol (2013) 25(2):130–45. doi:10.1016/j.
smim.2013.05.007 
19. Jackson LA, Campbell JD, Frey SE, Edwards KM, Keitel WA, Kotloff KL, 
et al. Effect of varying doses of a monovalent H7N9 influenza vaccine with 
and without AS03 and MF59 adjuvants on immune response: a randomized 
clinical trial. JAMA (2015) 314(3):237–46. doi:10.1001/jama.2015.7916 
20. Nolan T, Bravo L, Ceballos A, Mitha E, Gray G, Quiambao B, et  al. 
Enhanced and persistent antibody response against homologous and hetero- 
logous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and 
young children. Vaccine (2014) 32(46):6146–56. doi:10.1016/j.vaccine.2014. 
08.068 
21. Schmidt ST, Neustrup MA, Harloff-Helleberg S, Korsholm KS, Rades T, 
Andersen P, et al. Systematic investigation of the role of surfactant composition 
and choice of oil: design of a nanoemulsion-based adjuvant inducing concom-
itant humoral and CD4+ T-cell responses. Pharm Res (2017) 34(8):1716–27. 
doi:10.1007/s11095-017-2180-9 
22. Olsen AW, Follmann F, Erneholm K, Rosenkrands I, Andersen P. Protection 
against Chlamydia trachomatis infection and upper genital tract pathological 
changes by vaccine-promoted neutralizing antibodies directed to the VD4 
of the major outer membrane protein. J Infect Dis (2015) 212(6):978–89. 
doi:10.1093/infdis/jiv137 
23. Rose F, Wern JE, Gavins F, Andersen P, Follmann F, Foged C. A strong 
adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles 
potentiates mucosal immune responses against the recombinant Chlamydia 
trachomatis fusion antigen CTH522. J Control Release (2018) 271:88–97. 
doi:10.1016/j.jconrel.2017.12.003 
24. Nordly P, Korsholm KS, Pedersen EA, Khilji TS, Franzyk H, Jorgensen L, 
et  al. Incorporation of a synthetic mycobacterial monomycoloyl glycerol 
analogue stabilizes dimethyldioctadecylammonium liposomes and potenti-
ates their adjuvant effect in vivo. Eur J Pharm Biopharm (2011) 77(1):89–98. 
doi:10.1016/j.ejpb.2010.10.001 
25. Nordly P, Rose F, Christensen D, Nielsen HM, Andersen P, Agger EM, et al. 
Immunity by formulation design: induction of high CD8+ T-cell responses 
by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion 
method. J Control Release (2011) 150(3):307–17. doi:10.1016/j.jconrel.2010. 
11.021 
26. Korsholm KS, Karlsson I, Tang ST, Brandt L, Agger EM, Aagaard C, et  al. 
Broadening of the T-cell repertoire to HIV-1 Gag p24 by vaccination of HLA-
A2/DR transgenic mice with overlapping peptides in the CAF05 adjuvant. 
PLoS One (2013) 8(5):e63575. doi:10.1371/journal.pone.0063575 
27. Cantisani R, Pezzicoli A, Cioncada R, Malzone C, De Gregorio E, D’Oro U, 
et  al. Vaccine adjuvant MF59 promotes retention of unprocessed antigen 
in lymph node macrophage compartments and follicular dendritic cells. 
J Immunol (2015) 194(4):1717–25. doi:10.4049/jimmunol.1400623 
28. Karbach J, Gnjatic S, Bender A, Neumann A, Weidmann E, Yuan J, et  al. 
Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 
peptide, CpG 7909 and Montanide® ISA-51: association with survival. Int 
J Cancer (2010) 126(4):909–18. doi:10.1002/ijc.24850 
29. Speiser DE, Liénard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, et al. 
Rapid and strong human CD8+ T cell responses to vaccination with peptide, 
IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest (2005) 115(3):739–46. 
doi:10.1172/JCI23373 
30. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang X-F, et  al. 
Persistent antigen at vaccination sites induces tumor-specific CD8+ T  cell 
sequestration, dysfunction and deletion. Nat Med (2013) 19:465. doi:10.1038/
nm.3105 
31. Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, 
et al. Evaluation of peptide vaccine immunogenicity in draining lymph nodes 
and peripheral blood of melanoma patients. Int J Cancer (2001) 92(5):703–11. 
doi:10.1002/1097-0215(20010601)92:5<703::AID-IJC1250>3.0.CO;2-5 
32. van Doorn E, Liu H, Huckriede A, Hak E. Safety and tolerability evaluation 
of the use of Montanide ISA™51 as vaccine adjuvant: a systematic review. 
Hum Vaccin Immunother (2016) 12(1):159–69. doi:10.1080/21645515.2015.
1071455 
33. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo targe- 
ting of dendritic cells in lymph nodes with poly(propylene sulfide) nano-
particles. J Control Release (2006) 112(1):26–34. doi:10.1016/j.jconrel.2006. 
01.006 
34. Zhang C, Xu W, Chen J, Guan R, Bi S, Jin H, et al. Soybean oil containing gin-
seng saponins as adjuvants promotes production of cytokines and enhances 
12
Schmidt et al. Induction of CTL with CAF24a
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 898
immune responses to foot-and-mouth disease vaccine. Microbiol Immunol 
(2017) 62(3):187–94. doi:10.1111/348-0421.12567 
35. Abadie V, Badell E, Douillard P, Ensergueix D, Leenen PJM, Tanguy M, et al. 
Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG 
intradermal vaccination and shuttle live bacilli to the draining lymph nodes. 
Blood (2005) 106(5):1843–50. doi:10.1182/blood-2005-03-1281 
36. Hor JL, Heath WR, Mueller SN. Neutrophils are dispensable in the modulation 
of T cell immunity against cutaneous HSV-1 infection. Sci Rep (2017) 7:41091. 
doi:10.1038/srep41091 
37. Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic 
cells. Nat Rev Immunol (2015) 15(8):471–85. doi:10.1038/nri3865 
Conflict of Interest Statement: SS, GP, KK, PA, and DC are employed by Statens 
Serum Institut, which is a nonprofit government research facility, holding patents 
on the cationic adjuvant formulations (CAF).
Copyright © 2018 Schmidt, Pedersen, Neustrup, Korsholm, Rades, Andersen, 
Foged and Christensen. This is an open-access article distributed under the terms 
of the Creative Commons Attribution License (CC BY). The use, distribution or 
reproduction in other forums is permitted, provided the original author(s) and the 
copyright owner are credited and that the original publication in this journal is cited, 
in accordance with accepted academic practice. No use, distribution or reproduction 
is permitted which does not comply with these terms.
